LCTX
LCTX clinical trials: Lineage Cell Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Lineage Cell Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 5
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
LCTX on the catalyst calendar · LCTX registry changes
- Primary completion Aug 10, 2027Sponsor estimatePhase 1NCT06841770A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord InjuryLineage Cell Therapeutics, Inc. · Spinal Cord Injury CervicalRecruitingLCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2033Sponsor estimateNo phase registeredNCT05975424LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1Lineage Cell Therapeutics, Inc. · Spinal Cord InjuriesActive, not recruitingLCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2026Sponsor estimateNo phase registeredNCT05919563LTFU Study of Subjects Who Received GRNOPC1Lineage Cell Therapeutics, Inc. · Spinal Cord InjuriesActive, not recruitingLCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2018ActualPhase 1/Phase 2NCT02302157Dose Escalation Study of AST-OPC1 in Spinal Cord InjuryLineage Cell Therapeutics, Inc. · Cervical Spinal Cord InjuryCompletedLCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2013ActualPhase 1NCT01217008Safety Study of GRNOPC1 in Spinal Cord InjuryLineage Cell Therapeutics, Inc. · Spinal Cord InjuryCompletedLCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner